Nanotechnology as a Versatile Tool for 19F-MRI Agent's Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles
Creators
- 1. School of Pharmacy, University of Camerino, 62032 Camerino, Italy
- 2. Percuros B.V. Zernikedreef 8, 2333 CL Leiden, the Netherlands
- 3. School of Pharmacy, University of Camerino, 62032 Camerino
- 4. Dipartimento di Farmacia, Università "G. D'Annunzio" Chieti e Pescara, 66100 Chieti, Italy
Description
Simultaneously being a non-radiative and non-invasive technique makes magnetic resonance imaging (MRI) one of the highly sought imaging techniques for the early diagnosis and treatment of diseases. Despite more than four decades of research on finding a suitable imaging agent from fluorine for clinical applications, it still lingers as a challenge to get the regulatory approval compared to its hydrogen counterpart. The pertinent hurdle is the simultaneous intrinsic hydrophobicity and lipophobicity of fluorine and its derivatives that make them insoluble in any liquids, strongly limiting their application in areas such as targeted delivery. A blossoming technique to circumvent the unfavorable physicochemical characteristics of perfluorocarbon compounds (PFCs) and guarantee a high local concentration of fluorine in the desired body part is to encapsulate them in nanosystems. In this review, we will be emphasizing different types of nanocarrier systems studied to encapsulate various PFCs and fluorinated compounds, headway to be applied as a contrast agent (CA) in fluorine-19 MRI (19F MRI). We would also scrutinize, especially from studies over the last decade, the different types of PFCs and their specific applications and limitations concerning the nanoparticle (NP) system used to encapsulate them. A critical evaluation for future opportunities would be speculated.
Files
Nanotechnology as a Versatile Tool for 19F-MRI.pdf
Files
(12.4 MB)
Name | Size | Download all |
---|---|---|
md5:ed3ac70b9db84cf7ada0ff4e537b4eff
|
12.4 MB | Preview Download |
Additional details
Funding
- European Commission
- NOVA-MRI – Novel Applications in 19F Magnetic Resonance Imaging 859908
- European Commission
- CANCER – Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life 777682
- European Commission
- CAST – Active Monitoring of Cancer As An Alternative To Surgery 857894